Monthly Communication Report

Corporation:	Gilead Sciences Canada
Associated registration:	959600-360912-14
Communication date:	2025-01-28
Posted date:	2025-02-15

Designated Public Office Holders who participated in the communication:	Stephen Ellis, Member of Parliament House of Commons
List of Details Subject matter Detail Economic Development, Employment and Training, Health, Industry, Intellectual Property, Research and Development, Science and Technology Innovation Agenda, particularly with respect to initiatives to support and attract investments in the life sciences sector Health, Industry, Intellectual Property, International Trade, Research and Development, Science and Technology Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations Patented Medicine Prices Review Board (PMPRB) Regulations with regard to reporting requirements, pricing, guidelines and dispute resolution. Aboriginal Affairs, Health, Immigration, Industry, Research and Development, Science and Technology Policy and Programs Health Canada and Public Health Agency of Canada policies and programs to prevent and treat HIV and eliminate hepatitis as a public health threat by 2030, as part of Canada's commitments under the Global Viral Hepatitis Strategy and therapeutic efforts against the fight for COVID-19.
Responsible Officer who filed this communication report:	Paul Petrelli
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.